Connect your AI

Supernus Pharmaceuticals SUPN Earnings yield

Earnings yield at other companies

AbbVieABBV

0.9%-0.2pp

Rapport Therapeutics, Inc.RAPP

-7.2%-2.9pp

Axsome TherapeuticsAXSM

-2.2%-0.8pp

Neurocrine BiosciencesNBIX

5.1%+2.3pp

Jazz PharmaceuticalsJAZZ

-4.6%-11.2pp

Acadia PharmaceuticalsACAD

9.9%+1.6pp

Other financials

Income statement

Revenue$207.7M+38.6%

Gross profit$184.3M+37.5%

Operating income-$8.3M+18.8%

Net income-$2.3M+80.6%

EPS (diluted)-$0.04+81.0%

Balance sheet

Cash & equivalents$186.3M+60.8%

Total debt$40.9M+26.6%

Total equity$1.1B+4.5%

Total assets$1.5B+11.4%

Cash flow

Operating cash flow$66.5M+117%

CapEx--100%

Free cash flow$66.5M+120%

Valuation

Market cap$2.58B+62.8%

Enterprise value$2.44B+62.3%

P/S3.3×+0.9×

Profitability

Gross margin89.4%+1.0pp

Operating margin-7.8%-18.9pp

Net margin-3.7%-13.0pp

FCF margin27.9%+3.4pp

Returns & leverage

Return on equity-2.8%-9.1pp

Debt / equity0×0.0×

Current ratio2×-0.5×

Where this comes from

Calculated from Supernus Pharmaceuticals’s reported figures.

net income/market cap=-1%

Based on trailing twelve months.

The official record: Supernus Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Supernus Pharmaceuticals's earnings yield.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Supernus Pharmaceuticals's earnings yield?: Supernus Pharmaceuticals (SUPN) reported earnings yield of -1% in Q1 2026.
How has Supernus Pharmaceuticals's earnings yield changed year-over-year?: Supernus Pharmaceuticals's earnings yield decreased by 128.8% year-over-year, from 3.4% to -1%.
What is the long-term trend for Supernus Pharmaceuticals's earnings yield?: Over 5 years (2020 to 2025), Supernus Pharmaceuticals's earnings yield has grown at a -32.3% compound annual growth rate (CAGR), from 9.5% to -1.4%.
What does earnings yield mean?: Trailing-twelve-month net income divided by market capitalization at the quarter end — the inverse of the P/E ratio, expressed as a percentage.